| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 186 | 2024 | 196 | 39.660 |
Why?
|
| Peritoneal Dialysis | 150 | 2024 | 158 | 28.740 |
Why?
|
| Kidney Failure, Chronic | 163 | 2024 | 171 | 28.680 |
Why?
|
| Renal Dialysis | 106 | 2024 | 111 | 17.720 |
Why?
|
| Child | 440 | 2024 | 3364 | 13.380 |
Why?
|
| Humans | 579 | 2024 | 6896 | 12.700 |
Why?
|
| Kidney Transplantation | 94 | 2024 | 115 | 12.380 |
Why?
|
| Peritonitis | 53 | 2024 | 58 | 10.430 |
Why?
|
| Adolescent | 295 | 2024 | 2197 | 9.130 |
Why?
|
| Male | 344 | 2024 | 3337 | 9.120 |
Why?
|
| Female | 339 | 2024 | 3525 | 8.650 |
Why?
|
| Hypertension | 40 | 2024 | 66 | 8.650 |
Why?
|
| Glomerular Filtration Rate | 101 | 2024 | 115 | 8.500 |
Why?
|
| Kidney Diseases | 54 | 2020 | 71 | 7.550 |
Why?
|
| Child, Preschool | 204 | 2024 | 1569 | 6.840 |
Why?
|
| Infant | 176 | 2024 | 1446 | 6.160 |
Why?
|
| Anemia | 25 | 2023 | 25 | 6.100 |
Why?
|
| Hematinics | 15 | 2022 | 15 | 5.450 |
Why?
|
| Catheter-Related Infections | 19 | 2024 | 22 | 4.920 |
Why?
|
| Blood Pressure | 40 | 2024 | 67 | 4.620 |
Why?
|
| Prospective Studies | 113 | 2024 | 525 | 4.510 |
Why?
|
| Kidney | 48 | 2024 | 94 | 4.060 |
Why?
|
| Risk Factors | 88 | 2023 | 487 | 3.790 |
Why?
|
| Acute Kidney Injury | 17 | 2023 | 30 | 3.510 |
Why?
|
| Renal Replacement Therapy | 24 | 2023 | 26 | 3.400 |
Why?
|
| Disease Progression | 52 | 2023 | 111 | 3.240 |
Why?
|
| Adult | 76 | 2024 | 1181 | 3.140 |
Why?
|
| Cohort Studies | 64 | 2024 | 289 | 3.040 |
Why?
|
| Hyperparathyroidism, Secondary | 8 | 2020 | 9 | 3.020 |
Why?
|
| Cardiovascular Diseases | 16 | 2023 | 48 | 3.000 |
Why?
|
| Infant, Newborn | 64 | 2022 | 816 | 2.930 |
Why?
|
| Nephrology | 15 | 2023 | 19 | 2.880 |
Why?
|
| Proteinuria | 19 | 2024 | 28 | 2.810 |
Why?
|
| Catheters, Indwelling | 27 | 2024 | 31 | 2.700 |
Why?
|
| Treatment Outcome | 59 | 2023 | 622 | 2.690 |
Why?
|
| Creatinine | 41 | 2023 | 52 | 2.620 |
Why?
|
| Catheterization | 13 | 2023 | 29 | 2.580 |
Why?
|
| Quality of Life | 26 | 2023 | 140 | 2.500 |
Why?
|
| Retrospective Studies | 60 | 2023 | 1296 | 2.380 |
Why?
|
| Renal Insufficiency | 8 | 2023 | 10 | 2.330 |
Why?
|
| Graft Rejection | 19 | 2023 | 31 | 2.310 |
Why?
|
| Registries | 33 | 2023 | 92 | 2.310 |
Why?
|
| Erythropoietin | 17 | 2023 | 19 | 2.260 |
Why?
|
| Young Adult | 40 | 2023 | 647 | 2.260 |
Why?
|
| Time Factors | 52 | 2023 | 250 | 2.240 |
Why?
|
| Anti-Bacterial Agents | 18 | 2024 | 243 | 2.160 |
Why?
|
| Age Factors | 47 | 2021 | 210 | 2.150 |
Why?
|
| Nephritis, Hereditary | 4 | 2023 | 4 | 2.090 |
Why?
|
| Cognition | 13 | 2023 | 32 | 2.060 |
Why?
|
| Practice Guidelines as Topic | 18 | 2024 | 108 | 2.050 |
Why?
|
| Dialysis Solutions | 17 | 2021 | 19 | 2.010 |
Why?
|
| Nutritional Status | 13 | 2024 | 17 | 1.930 |
Why?
|
| Hypertrophy, Left Ventricular | 15 | 2024 | 16 | 1.860 |
Why?
|
| Hemoglobins | 20 | 2023 | 27 | 1.760 |
Why?
|
| Body Height | 23 | 2021 | 34 | 1.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 39 | 1.730 |
Why?
|
| United States | 51 | 2023 | 669 | 1.730 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 7 | 2023 | 22 | 1.710 |
Why?
|
| Pediatrics | 14 | 2021 | 186 | 1.690 |
Why?
|
| Growth Disorders | 14 | 2021 | 25 | 1.670 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 14 | 2011 | 14 | 1.600 |
Why?
|
| Graft Survival | 21 | 2020 | 31 | 1.600 |
Why?
|
| Longitudinal Studies | 40 | 2024 | 119 | 1.590 |
Why?
|
| Child Development | 12 | 2019 | 44 | 1.580 |
Why?
|
| Cross-Sectional Studies | 48 | 2023 | 336 | 1.550 |
Why?
|
| Peritoneum | 15 | 2021 | 16 | 1.540 |
Why?
|
| Arteriovenous Shunt, Surgical | 7 | 2021 | 7 | 1.510 |
Why?
|
| Hyperammonemia | 2 | 2021 | 2 | 1.500 |
Why?
|
| Risk Assessment | 30 | 2020 | 137 | 1.490 |
Why?
|
| Quality Improvement | 9 | 2021 | 60 | 1.480 |
Why?
|
| Calcimimetic Agents | 3 | 2020 | 7 | 1.460 |
Why?
|
| Follow-Up Studies | 38 | 2021 | 304 | 1.450 |
Why?
|
| Biomarkers | 31 | 2024 | 136 | 1.450 |
Why?
|
| Consensus | 5 | 2020 | 35 | 1.450 |
Why?
|
| Histocompatibility Testing | 17 | 2016 | 22 | 1.340 |
Why?
|
| Patient Selection | 5 | 2020 | 40 | 1.330 |
Why?
|
| Anemia, Iron-Deficiency | 3 | 2018 | 5 | 1.320 |
Why?
|
| Ferric Compounds | 5 | 2022 | 5 | 1.310 |
Why?
|
| Prevalence | 35 | 2020 | 146 | 1.280 |
Why?
|
| Body Mass Index | 16 | 2022 | 157 | 1.280 |
Why?
|
| Vascular Stiffness | 4 | 2023 | 5 | 1.270 |
Why?
|
| Chronic Disease | 33 | 2021 | 105 | 1.270 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 16 | 2024 | 19 | 1.220 |
Why?
|
| Iron | 8 | 2023 | 14 | 1.190 |
Why?
|
| Anti-Infective Agents, Local | 4 | 2024 | 8 | 1.190 |
Why?
|
| Cystatin C | 10 | 2021 | 11 | 1.160 |
Why?
|
| Dietary Supplements | 5 | 2024 | 25 | 1.140 |
Why?
|
| North America | 28 | 2021 | 44 | 1.110 |
Why?
|
| Hypothyroidism | 3 | 2023 | 4 | 1.110 |
Why?
|
| Hyperphosphatemia | 6 | 2021 | 10 | 1.100 |
Why?
|
| Hospitalization | 9 | 2022 | 210 | 1.090 |
Why?
|
| Child Behavior | 7 | 2020 | 30 | 1.090 |
Why?
|
| Iodine | 2 | 2023 | 3 | 1.080 |
Why?
|
| Pediatric Obesity | 5 | 2021 | 137 | 1.080 |
Why?
|
| Blood Pressure Determination | 9 | 2023 | 14 | 1.070 |
Why?
|
| Oleanolic Acid | 2 | 2022 | 2 | 1.050 |
Why?
|
| Diabetic Nephropathies | 3 | 2024 | 4 | 1.050 |
Why?
|
| Cognition Disorders | 4 | 2014 | 12 | 1.040 |
Why?
|
| Central Venous Catheters | 3 | 2024 | 5 | 1.030 |
Why?
|
| Severity of Illness Index | 25 | 2021 | 149 | 1.000 |
Why?
|
| Kidney Function Tests | 16 | 2023 | 22 | 1.000 |
Why?
|
| Biopsy | 7 | 2023 | 60 | 1.000 |
Why?
|
| Human Growth Hormone | 10 | 2021 | 15 | 0.990 |
Why?
|
| Catheterization, Central Venous | 4 | 2024 | 18 | 0.990 |
Why?
|
| Parathyroid Hormone | 13 | 2020 | 24 | 0.980 |
Why?
|
| Tissue Donors | 18 | 2020 | 30 | 0.980 |
Why?
|
| Adolescent Behavior | 6 | 2018 | 43 | 0.980 |
Why?
|
| Chlorhexidine | 2 | 2024 | 3 | 0.970 |
Why?
|
| Observer Variation | 1 | 2024 | 16 | 0.960 |
Why?
|
| Naphthyridines | 1 | 2024 | 1 | 0.950 |
Why?
|
| Ambulatory Care Facilities | 2 | 2022 | 36 | 0.940 |
Why?
|
| Diastole | 2 | 2021 | 11 | 0.940 |
Why?
|
| Polycystic Kidney Diseases | 2 | 2023 | 3 | 0.920 |
Why?
|
| Telemedicine | 2 | 2022 | 59 | 0.900 |
Why?
|
| Darbepoetin alfa | 4 | 2022 | 4 | 0.900 |
Why?
|
| Goals | 2 | 2020 | 6 | 0.900 |
Why?
|
| Reoperation | 8 | 2016 | 59 | 0.900 |
Why?
|
| Incidence | 15 | 2020 | 133 | 0.860 |
Why?
|
| Dyslipidemias | 5 | 2019 | 15 | 0.860 |
Why?
|
| Double-Blind Method | 7 | 2022 | 44 | 0.850 |
Why?
|
| Kidney Neoplasms | 4 | 2017 | 11 | 0.850 |
Why?
|
| Physicians | 1 | 2022 | 23 | 0.830 |
Why?
|
| Vitamin D | 8 | 2024 | 22 | 0.820 |
Why?
|
| Nephrotic Syndrome | 5 | 2023 | 29 | 0.800 |
Why?
|
| Vitamin D Deficiency | 5 | 2024 | 11 | 0.790 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 6 | 0.780 |
Why?
|
| Phosphorus | 8 | 2021 | 8 | 0.770 |
Why?
|
| HLA-DR Antigens | 5 | 2016 | 7 | 0.770 |
Why?
|
| ABO Blood-Group System | 9 | 2007 | 11 | 0.770 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2020 | 3 | 0.750 |
Why?
|
| Catheterization, Peripheral | 1 | 2021 | 5 | 0.750 |
Why?
|
| Specimen Handling | 1 | 2021 | 17 | 0.750 |
Why?
|
| Survival Rate | 13 | 2021 | 83 | 0.730 |
Why?
|
| Mycoses | 4 | 2018 | 12 | 0.720 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2020 | 2 | 0.720 |
Why?
|
| Enteral Nutrition | 6 | 2020 | 63 | 0.720 |
Why?
|
| Multivariate Analysis | 22 | 2017 | 71 | 0.710 |
Why?
|
| Immunosuppressive Agents | 8 | 2014 | 31 | 0.700 |
Why?
|
| Kidney Diseases, Cystic | 3 | 2017 | 7 | 0.680 |
Why?
|
| Health Literacy | 2 | 2018 | 4 | 0.680 |
Why?
|
| Chelating Agents | 2 | 2017 | 2 | 0.670 |
Why?
|
| Echocardiography | 9 | 2024 | 81 | 0.670 |
Why?
|
| Executive Function | 7 | 2023 | 10 | 0.670 |
Why?
|
| Mycobacterium fortuitum | 1 | 2019 | 2 | 0.660 |
Why?
|
| Medication Adherence | 4 | 2014 | 21 | 0.660 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 2 | 0.660 |
Why?
|
| Secondary Prevention | 3 | 2017 | 7 | 0.660 |
Why?
|
| Antihypertensive Agents | 10 | 2023 | 13 | 0.660 |
Why?
|
| Hypotension | 1 | 2019 | 5 | 0.660 |
Why?
|
| Fibroblast Growth Factors | 6 | 2023 | 30 | 0.660 |
Why?
|
| Urea | 11 | 2005 | 12 | 0.660 |
Why?
|
| Urogenital Abnormalities | 4 | 2022 | 12 | 0.660 |
Why?
|
| Prognosis | 15 | 2020 | 211 | 0.650 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 10 | 2024 | 15 | 0.650 |
Why?
|
| Models, Biological | 7 | 2012 | 65 | 0.650 |
Why?
|
| Iohexol | 12 | 2020 | 12 | 0.640 |
Why?
|
| Diphosphates | 1 | 2018 | 1 | 0.640 |
Why?
|
| Child Nutritional Physiological Phenomena | 8 | 2024 | 11 | 0.640 |
Why?
|
| Histocompatibility Antigens Class I | 8 | 2013 | 11 | 0.630 |
Why?
|
| Intelligence | 7 | 2023 | 8 | 0.630 |
Why?
|
| Bacterial Infections | 6 | 2007 | 27 | 0.610 |
Why?
|
| Glomerulonephritis | 4 | 2015 | 8 | 0.610 |
Why?
|
| Patient Care Management | 1 | 2017 | 3 | 0.610 |
Why?
|
| Europe | 13 | 2021 | 37 | 0.610 |
Why?
|
| Agammaglobulinemia | 2 | 2016 | 2 | 0.600 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 4 | 2020 | 5 | 0.600 |
Why?
|
| Body Weight | 10 | 2016 | 52 | 0.600 |
Why?
|
| Sevelamer | 1 | 2017 | 1 | 0.600 |
Why?
|
| Kidd Blood-Group System | 2 | 2008 | 2 | 0.600 |
Why?
|
| Hyperkalemia | 4 | 2023 | 4 | 0.600 |
Why?
|
| Disease Management | 2 | 2014 | 34 | 0.590 |
Why?
|
| HLA-DQ Antigens | 2 | 2016 | 4 | 0.590 |
Why?
|
| Recombinant Proteins | 17 | 2021 | 48 | 0.590 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 2 | 0.590 |
Why?
|
| Hypoalbuminemia | 2 | 2015 | 5 | 0.570 |
Why?
|
| Ventricular Function, Left | 5 | 2024 | 28 | 0.560 |
Why?
|
| Linear Models | 18 | 2017 | 56 | 0.560 |
Why?
|
| Sodium | 2 | 2016 | 7 | 0.560 |
Why?
|
| Transplant Recipients | 4 | 2023 | 9 | 0.560 |
Why?
|
| Waiting Lists | 9 | 2022 | 12 | 0.560 |
Why?
|
| Donor Selection | 1 | 2016 | 2 | 0.560 |
Why?
|
| Urinary Tract | 4 | 2022 | 10 | 0.560 |
Why?
|
| Infant, Low Birth Weight | 3 | 2010 | 14 | 0.550 |
Why?
|
| Logistic Models | 15 | 2022 | 84 | 0.540 |
Why?
|
| Diet | 5 | 2023 | 52 | 0.530 |
Why?
|
| Calcium | 9 | 2020 | 41 | 0.530 |
Why?
|
| Socioeconomic Factors | 8 | 2021 | 53 | 0.520 |
Why?
|
| Growth | 8 | 2009 | 11 | 0.520 |
Why?
|
| Survival Analysis | 12 | 2017 | 50 | 0.520 |
Why?
|
| Health Expenditures | 1 | 2015 | 15 | 0.510 |
Why?
|
| Global Health | 3 | 2014 | 15 | 0.510 |
Why?
|
| Health Care Costs | 1 | 2015 | 33 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 35 | 0.500 |
Why?
|
| Ambulatory Care | 1 | 2015 | 45 | 0.500 |
Why?
|
| Metabolome | 3 | 2024 | 5 | 0.500 |
Why?
|
| Contrast Media | 9 | 2023 | 23 | 0.500 |
Why?
|
| Overweight | 3 | 2021 | 49 | 0.500 |
Why?
|
| Masked Hypertension | 3 | 2022 | 3 | 0.500 |
Why?
|
| Middle Aged | 10 | 2022 | 608 | 0.490 |
Why?
|
| Surveys and Questionnaires | 15 | 2023 | 274 | 0.490 |
Why?
|
| Bicarbonates | 5 | 2022 | 8 | 0.490 |
Why?
|
| Hemodiafiltration | 4 | 2021 | 4 | 0.490 |
Why?
|
| Urology | 1 | 2014 | 7 | 0.480 |
Why?
|
| Educational Status | 6 | 2023 | 21 | 0.480 |
Why?
|
| Hemodialysis Solutions | 3 | 2019 | 3 | 0.480 |
Why?
|
| Caregivers | 4 | 2022 | 40 | 0.480 |
Why?
|
| Metabolomics | 3 | 2023 | 18 | 0.480 |
Why?
|
| Patient Care | 1 | 2014 | 6 | 0.470 |
Why?
|
| Immunoglobulin G | 11 | 2016 | 34 | 0.470 |
Why?
|
| Carnitine | 3 | 2021 | 5 | 0.460 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 130 | 0.460 |
Why?
|
| Albuminuria | 5 | 2023 | 12 | 0.450 |
Why?
|
| Vitamins | 3 | 2024 | 11 | 0.450 |
Why?
|
| Growth Hormone | 5 | 2005 | 6 | 0.450 |
Why?
|
| Vesico-Ureteral Reflux | 5 | 2022 | 6 | 0.450 |
Why?
|
| Parents | 7 | 2023 | 157 | 0.450 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 22 | 0.450 |
Why?
|
| Recurrence | 10 | 2023 | 110 | 0.440 |
Why?
|
| Patient Compliance | 4 | 2016 | 55 | 0.440 |
Why?
|
| Glucaric Acid | 1 | 2012 | 1 | 0.430 |
Why?
|
| Sex Factors | 10 | 2020 | 68 | 0.430 |
Why?
|
| Attention | 4 | 2020 | 13 | 0.420 |
Why?
|
| Child Health Services | 1 | 2012 | 24 | 0.420 |
Why?
|
| Case-Control Studies | 12 | 2023 | 215 | 0.420 |
Why?
|
| Nutritional Requirements | 4 | 2019 | 7 | 0.420 |
Why?
|
| Calcifediol | 1 | 2012 | 3 | 0.420 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 30 | 0.410 |
Why?
|
| Aged | 5 | 2022 | 378 | 0.410 |
Why?
|
| Neuropsychological Tests | 8 | 2020 | 15 | 0.400 |
Why?
|
| Cimetidine | 3 | 2003 | 3 | 0.400 |
Why?
|
| Dietary Proteins | 6 | 2023 | 8 | 0.400 |
Why?
|
| Hemodialysis, Home | 3 | 2023 | 4 | 0.400 |
Why?
|
| Antibodies | 3 | 2008 | 15 | 0.400 |
Why?
|
| Acidosis | 2 | 2022 | 3 | 0.390 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 45 | 0.380 |
Why?
|
| Research Design | 4 | 2021 | 63 | 0.380 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2010 | 1 | 0.370 |
Why?
|
| Body Water | 4 | 2005 | 5 | 0.370 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 26 | 0.370 |
Why?
|
| Histamine H2 Antagonists | 2 | 2003 | 7 | 0.370 |
Why?
|
| Pseudotumor Cerebri | 1 | 2010 | 1 | 0.370 |
Why?
|
| Cadaver | 16 | 2007 | 19 | 0.360 |
Why?
|
| Delphi Technique | 2 | 2020 | 11 | 0.360 |
Why?
|
| Gastrostomy | 3 | 2019 | 63 | 0.360 |
Why?
|
| Pandemics | 2 | 2022 | 82 | 0.360 |
Why?
|
| Erythrocytes | 2 | 2018 | 11 | 0.350 |
Why?
|
| Lupus Nephritis | 3 | 2021 | 3 | 0.350 |
Why?
|
| Peritoneal Fibrosis | 1 | 2010 | 1 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2024 | 19 | 0.350 |
Why?
|
| Living Donors | 3 | 2007 | 7 | 0.350 |
Why?
|
| Odds Ratio | 11 | 2017 | 51 | 0.350 |
Why?
|
| Colostomy | 2 | 2019 | 6 | 0.350 |
Why?
|
| Infant, Premature | 1 | 2010 | 85 | 0.350 |
Why?
|
| Arterioles | 2 | 2021 | 3 | 0.350 |
Why?
|
| Phthalic Acids | 2 | 2020 | 2 | 0.350 |
Why?
|
| Benzhydryl Compounds | 2 | 2020 | 3 | 0.350 |
Why?
|
| Phenols | 2 | 2020 | 7 | 0.350 |
Why?
|
| Developmental Disabilities | 3 | 2009 | 43 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 85 | 0.350 |
Why?
|
| Postoperative Complications | 4 | 2021 | 184 | 0.350 |
Why?
|
| Social Work | 1 | 2009 | 3 | 0.340 |
Why?
|
| Continuity of Patient Care | 1 | 2009 | 6 | 0.340 |
Why?
|
| Obesity | 4 | 2022 | 125 | 0.340 |
Why?
|
| Vascular Diseases | 2 | 2021 | 8 | 0.340 |
Why?
|
| Guideline Adherence | 4 | 2019 | 36 | 0.340 |
Why?
|
| Glucose | 5 | 2021 | 22 | 0.340 |
Why?
|
| Patient-Centered Care | 1 | 2009 | 16 | 0.340 |
Why?
|
| Cause of Death | 5 | 2021 | 13 | 0.340 |
Why?
|
| Comorbidity | 9 | 2020 | 56 | 0.340 |
Why?
|
| Tissue and Organ Procurement | 10 | 2009 | 17 | 0.340 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2021 | 30 | 0.340 |
Why?
|
| Candidiasis | 2 | 2000 | 5 | 0.340 |
Why?
|
| Arginine | 2 | 2020 | 3 | 0.330 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2016 | 5 | 0.330 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 17 | 0.330 |
Why?
|
| Inulin | 5 | 1998 | 5 | 0.320 |
Why?
|
| Immunity, Humoral | 2 | 2022 | 14 | 0.320 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2024 | 3 | 0.320 |
Why?
|
| Point-of-Care Systems | 1 | 2008 | 10 | 0.320 |
Why?
|
| Fibrosis | 2 | 2018 | 4 | 0.320 |
Why?
|
| Antigens | 1 | 2008 | 3 | 0.320 |
Why?
|
| Feeding Behavior | 3 | 2017 | 50 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2018 | 348 | 0.310 |
Why?
|
| Fractures, Bone | 2 | 2020 | 34 | 0.310 |
Why?
|
| Kidney Glomerulus | 5 | 2023 | 19 | 0.310 |
Why?
|
| Canada | 10 | 2020 | 31 | 0.310 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 8 | 0.310 |
Why?
|
| Heart Rate | 4 | 2017 | 26 | 0.300 |
Why?
|
| Treatment Refusal | 2 | 2018 | 4 | 0.300 |
Why?
|
| Predictive Value of Tests | 11 | 2020 | 99 | 0.300 |
Why?
|
| Office Visits | 3 | 2018 | 4 | 0.300 |
Why?
|
| Sleep Wake Disorders | 2 | 2023 | 22 | 0.300 |
Why?
|
| Self Care | 3 | 2021 | 22 | 0.300 |
Why?
|
| Hypocalcemia | 3 | 2019 | 4 | 0.300 |
Why?
|
| Administration, Oral | 6 | 2018 | 58 | 0.300 |
Why?
|
| Nutrition Assessment | 3 | 2023 | 5 | 0.300 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 6 | 0.290 |
Why?
|
| Kidney Tubules | 3 | 2023 | 3 | 0.290 |
Why?
|
| Plasma Cells | 1 | 2006 | 1 | 0.290 |
Why?
|
| Blood Urea Nitrogen | 9 | 2017 | 9 | 0.280 |
Why?
|
| Uric Acid | 3 | 2022 | 6 | 0.280 |
Why?
|
| Nephelometry and Turbidimetry | 2 | 2019 | 2 | 0.280 |
Why?
|
| Psychology, Adolescent | 2 | 2009 | 6 | 0.280 |
Why?
|
| Skin Diseases | 1 | 2006 | 2 | 0.280 |
Why?
|
| Patient Care Bundles | 2 | 2016 | 3 | 0.280 |
Why?
|
| Phosphates | 4 | 2022 | 13 | 0.270 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 53 | 0.270 |
Why?
|
| Adaptation, Psychological | 3 | 2020 | 39 | 0.270 |
Why?
|
| Hypertriglyceridemia | 3 | 2016 | 5 | 0.270 |
Why?
|
| Data Collection | 4 | 2020 | 29 | 0.270 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2016 | 6 | 0.270 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 26 | 0.270 |
Why?
|
| Chi-Square Distribution | 9 | 2017 | 33 | 0.270 |
Why?
|
| Collagen Type IV | 2 | 2023 | 3 | 0.260 |
Why?
|
| Hematuria | 2 | 2023 | 6 | 0.260 |
Why?
|
| Povidone-Iodine | 2 | 2023 | 3 | 0.260 |
Why?
|
| Transferrin | 4 | 2012 | 4 | 0.260 |
Why?
|
| Echocardiography, Doppler | 3 | 2014 | 11 | 0.260 |
Why?
|
| Vancomycin | 2 | 2020 | 17 | 0.250 |
Why?
|
| Animals | 11 | 2023 | 729 | 0.250 |
Why?
|
| Machine Learning | 2 | 2022 | 17 | 0.250 |
Why?
|
| Inflammation | 3 | 2023 | 51 | 0.250 |
Why?
|
| Protein-Energy Malnutrition | 2 | 2014 | 2 | 0.250 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 42 | 0.250 |
Why?
|
| Ergocalciferols | 2 | 2017 | 2 | 0.250 |
Why?
|
| HLA Antigens | 4 | 2013 | 13 | 0.250 |
Why?
|
| Genome-Wide Association Study | 4 | 2023 | 190 | 0.250 |
Why?
|
| Asia | 6 | 2021 | 10 | 0.250 |
Why?
|
| Tissue Banks | 6 | 1999 | 6 | 0.250 |
Why?
|
| Health Surveys | 2 | 2004 | 15 | 0.240 |
Why?
|
| Chemokine CCL2 | 2 | 2021 | 3 | 0.240 |
Why?
|
| Flow Cytometry | 2 | 2002 | 32 | 0.240 |
Why?
|
| Hypercalcemia | 4 | 2019 | 10 | 0.240 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 47 | 0.240 |
Why?
|
| Body Surface Area | 7 | 2012 | 11 | 0.240 |
Why?
|
| Psychotropic Drugs | 1 | 2024 | 3 | 0.240 |
Why?
|
| Energy Intake | 4 | 2017 | 34 | 0.240 |
Why?
|
| Diet, Protein-Restricted | 2 | 2023 | 2 | 0.240 |
Why?
|
| Review Literature as Topic | 1 | 2024 | 1 | 0.240 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 1 | 0.240 |
Why?
|
| Standard of Care | 3 | 2019 | 5 | 0.240 |
Why?
|
| Heart Ventricles | 3 | 2024 | 49 | 0.230 |
Why?
|
| Intelligence Tests | 3 | 2013 | 4 | 0.230 |
Why?
|
| Laughter | 1 | 2004 | 1 | 0.230 |
Why?
|
| Epoetin Alfa | 2 | 2022 | 3 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 94 | 0.230 |
Why?
|
| Nutritional Support | 2 | 2023 | 5 | 0.230 |
Why?
|
| Blood Grouping and Crossmatching | 5 | 2007 | 5 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 55 | 0.230 |
Why?
|
| Advisory Committees | 2 | 2020 | 9 | 0.230 |
Why?
|
| Health Status | 3 | 2015 | 25 | 0.230 |
Why?
|
| Music | 1 | 2004 | 11 | 0.230 |
Why?
|
| Transplantation, Homologous | 6 | 2023 | 19 | 0.230 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2020 | 3 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 4 | 0.230 |
Why?
|
| Employment | 1 | 2023 | 5 | 0.230 |
Why?
|
| Mexico | 2 | 2017 | 5 | 0.230 |
Why?
|
| Aorta | 2 | 2014 | 8 | 0.220 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 6 | 0.220 |
Why?
|
| Africa | 1 | 2023 | 3 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 12 | 0.220 |
Why?
|
| Oxidative Stress | 2 | 2020 | 17 | 0.220 |
Why?
|
| Length of Stay | 2 | 2022 | 233 | 0.220 |
Why?
|
| Camping | 2 | 1994 | 2 | 0.220 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 17 | 0.220 |
Why?
|
| Societies, Medical | 2 | 2020 | 51 | 0.220 |
Why?
|
| Feasibility Studies | 3 | 2019 | 58 | 0.220 |
Why?
|
| Coombs Test | 2 | 2002 | 2 | 0.220 |
Why?
|
| Longevity | 1 | 2022 | 3 | 0.220 |
Why?
|
| Hypertension, Renal | 2 | 2013 | 4 | 0.220 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 18 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 15 | 0.210 |
Why?
|
| Reproducibility of Results | 9 | 2022 | 199 | 0.210 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 34 | 0.210 |
Why?
|
| Histoplasmosis | 1 | 2022 | 3 | 0.210 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 18 | 0.210 |
Why?
|
| Vomiting | 2 | 2021 | 23 | 0.210 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2002 | 1 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 65 | 0.210 |
Why?
|
| Potassium | 3 | 2023 | 9 | 0.210 |
Why?
|
| Osteomyelitis | 1 | 2022 | 8 | 0.210 |
Why?
|
| Nausea | 2 | 2021 | 16 | 0.210 |
Why?
|
| Albumins | 3 | 2006 | 7 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2002 | 6 | 0.210 |
Why?
|
| Isoantibodies | 5 | 2006 | 8 | 0.210 |
Why?
|
| Vaccination | 1 | 2022 | 71 | 0.210 |
Why?
|
| Abdominal Pain | 2 | 1994 | 71 | 0.200 |
Why?
|
| Central Nervous System | 1 | 2002 | 9 | 0.200 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2002 | 1 | 0.200 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 39 | 0.200 |
Why?
|
| Glutathione Transferase | 1 | 2021 | 2 | 0.200 |
Why?
|
| Plant Proteins | 1 | 2021 | 3 | 0.200 |
Why?
|
| Ehrlichiosis | 1 | 2021 | 1 | 0.200 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 1 | 0.200 |
Why?
|
| Alpha-Globulins | 1 | 2021 | 1 | 0.200 |
Why?
|
| Epidermal Growth Factor | 1 | 2021 | 1 | 0.200 |
Why?
|
| Pseudouridine | 1 | 2021 | 1 | 0.200 |
Why?
|
| Uridine | 1 | 2021 | 1 | 0.200 |
Why?
|
| Adenosine | 1 | 2021 | 8 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2020 | 3 | 0.200 |
Why?
|
| Life Change Events | 1 | 2021 | 3 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2021 | 38 | 0.190 |
Why?
|
| Communication | 2 | 2020 | 46 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2008 | 4 | 0.190 |
Why?
|
| Pesticides | 1 | 2021 | 1 | 0.190 |
Why?
|
| Morbidity | 3 | 2015 | 11 | 0.190 |
Why?
|
| Tobacco Products | 1 | 2021 | 2 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 18 | 0.190 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.190 |
Why?
|
| Software Validation | 1 | 2001 | 1 | 0.190 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2001 | 2 | 0.190 |
Why?
|
| Palliative Care | 2 | 2018 | 16 | 0.190 |
Why?
|
| Calcium Channels, L-Type | 1 | 2021 | 5 | 0.190 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 7 | 0.190 |
Why?
|
| Bacteriological Techniques | 1 | 2021 | 7 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2001 | 26 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2021 | 9 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 13 | 0.190 |
Why?
|
| Stroke | 2 | 2020 | 22 | 0.190 |
Why?
|
| Gram-Positive Bacteria | 1 | 2020 | 1 | 0.190 |
Why?
|
| Prednisone | 4 | 2017 | 12 | 0.190 |
Why?
|
| Chromosome Deletion | 2 | 2018 | 20 | 0.180 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2019 | 2 | 0.180 |
Why?
|
| Peptides | 1 | 2020 | 11 | 0.180 |
Why?
|
| Patient Preference | 1 | 2020 | 4 | 0.180 |
Why?
|
| Menarche | 1 | 2020 | 4 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 4 | 0.180 |
Why?
|
| Phenylacetates | 1 | 2020 | 1 | 0.180 |
Why?
|
| Phenylbutyrates | 1 | 2020 | 1 | 0.180 |
Why?
|
| Sodium Benzoate | 1 | 2020 | 1 | 0.180 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 2 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2020 | 1 | 0.180 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2020 | 2 | 0.180 |
Why?
|
| Parenteral Nutrition | 1 | 2020 | 7 | 0.180 |
Why?
|
| Infection Control | 1 | 2020 | 7 | 0.180 |
Why?
|
| Ferritins | 3 | 2012 | 4 | 0.180 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2016 | 8 | 0.180 |
Why?
|
| Adolescent Development | 2 | 2018 | 4 | 0.180 |
Why?
|
| Biomedical Research | 2 | 2014 | 27 | 0.180 |
Why?
|
| Aortic Diseases | 1 | 2020 | 4 | 0.180 |
Why?
|
| Immunophenotyping | 3 | 2016 | 7 | 0.180 |
Why?
|
| Hand Strength | 1 | 2020 | 7 | 0.180 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 35 | 0.180 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 15 | 0.180 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 16 | 0.180 |
Why?
|
| Reference Values | 7 | 2021 | 39 | 0.180 |
Why?
|
| Electrolytes | 2 | 2011 | 11 | 0.170 |
Why?
|
| Calcium, Dietary | 1 | 2019 | 7 | 0.170 |
Why?
|
| T-Lymphocytes | 3 | 2007 | 31 | 0.170 |
Why?
|
| Half-Life | 2 | 2018 | 12 | 0.170 |
Why?
|
| Capnocytophaga | 1 | 1999 | 1 | 0.170 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.170 |
Why?
|
| Poisoning | 1 | 2019 | 5 | 0.170 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2003 | 6 | 0.170 |
Why?
|
| Infant Mortality | 3 | 2021 | 4 | 0.170 |
Why?
|
| Sepsis | 1 | 2019 | 23 | 0.170 |
Why?
|
| Intestines | 1 | 1999 | 29 | 0.170 |
Why?
|
| Thinness | 1 | 2019 | 7 | 0.170 |
Why?
|
| Bacteremia | 1 | 1999 | 25 | 0.170 |
Why?
|
| Midodrine | 1 | 2019 | 1 | 0.170 |
Why?
|
| Temperature | 1 | 2019 | 12 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2019 | 24 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 1999 | 7 | 0.160 |
Why?
|
| Placebos | 1 | 2018 | 4 | 0.160 |
Why?
|
| Underachievement | 1 | 2018 | 1 | 0.160 |
Why?
|
| Fatigue | 3 | 2023 | 15 | 0.160 |
Why?
|
| Hospital Costs | 1 | 2019 | 29 | 0.160 |
Why?
|
| Blood Group Incompatibility | 5 | 2006 | 5 | 0.160 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 37 | 0.160 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 3 | 0.160 |
Why?
|
| Waist-Height Ratio | 1 | 2018 | 1 | 0.160 |
Why?
|
| Midwestern United States | 8 | 2017 | 34 | 0.160 |
Why?
|
| Autoantibodies | 2 | 2006 | 11 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2009 | 14 | 0.160 |
Why?
|
| Adiposity | 1 | 2018 | 10 | 0.160 |
Why?
|
| Ethics Committees, Clinical | 1 | 2018 | 2 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 99 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2019 | 87 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 1998 | 1 | 0.150 |
Why?
|
| Phosphatidylglycerols | 1 | 1998 | 1 | 0.150 |
Why?
|
| Pregnancy, High-Risk | 1 | 1998 | 1 | 0.150 |
Why?
|
| Phosphatidylcholines | 1 | 1998 | 2 | 0.150 |
Why?
|
| Fluconazole | 1 | 1998 | 2 | 0.150 |
Why?
|
| Amphotericin B | 1 | 1998 | 2 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 1998 | 7 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2017 | 2 | 0.150 |
Why?
|
| Waist Circumference | 1 | 2017 | 4 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 1998 | 13 | 0.150 |
Why?
|
| Complement Activation | 1 | 2017 | 2 | 0.150 |
Why?
|
| Complement System Proteins | 1 | 2017 | 5 | 0.150 |
Why?
|
| Cholesterol, HDL | 3 | 2014 | 10 | 0.150 |
Why?
|
| Carbon Dioxide | 2 | 2023 | 14 | 0.150 |
Why?
|
| Pregnancy | 3 | 2022 | 216 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2017 | 19 | 0.150 |
Why?
|
| International Cooperation | 4 | 2020 | 9 | 0.150 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2019 | 6 | 0.150 |
Why?
|
| Mutation | 2 | 2011 | 212 | 0.150 |
Why?
|
| Allografts | 3 | 2023 | 7 | 0.150 |
Why?
|
| Weight Loss | 1 | 2017 | 39 | 0.150 |
Why?
|
| Urologic Diseases | 1 | 1997 | 3 | 0.150 |
Why?
|
| Pancreatitis | 1 | 1997 | 8 | 0.150 |
Why?
|
| Transition to Adult Care | 2 | 2014 | 19 | 0.150 |
Why?
|
| Equipment Design | 4 | 2023 | 14 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 10 | 0.140 |
Why?
|
| Hematocrit | 4 | 2008 | 5 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 13 | 0.140 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2017 | 20 | 0.140 |
Why?
|
| Haploinsufficiency | 1 | 2017 | 10 | 0.140 |
Why?
|
| DiGeorge Syndrome | 1 | 2017 | 8 | 0.140 |
Why?
|
| Nose | 1 | 1997 | 7 | 0.140 |
Why?
|
| Cell Membrane Permeability | 1 | 1996 | 1 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 5 | 0.140 |
Why?
|
| Nephrectomy | 3 | 2006 | 14 | 0.140 |
Why?
|
| Wilms Tumor | 1 | 1996 | 2 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 10 | 0.140 |
Why?
|
| Heart | 1 | 2016 | 14 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 52 | 0.140 |
Why?
|
| Laparoscopy | 1 | 2019 | 207 | 0.140 |
Why?
|
| Epitopes | 1 | 2016 | 20 | 0.140 |
Why?
|
| Eating | 3 | 2023 | 31 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 41 | 0.140 |
Why?
|
| Calcinosis | 2 | 1994 | 6 | 0.140 |
Why?
|
| Tacrolimus | 2 | 2014 | 10 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 3 | 2020 | 19 | 0.140 |
Why?
|
| Aftercare | 1 | 2016 | 5 | 0.140 |
Why?
|
| Dwarfism | 2 | 2020 | 4 | 0.140 |
Why?
|
| Phosphorus, Dietary | 1 | 2016 | 1 | 0.140 |
Why?
|
| Aging | 2 | 2014 | 39 | 0.140 |
Why?
|
| Regression Analysis | 6 | 2014 | 52 | 0.140 |
Why?
|
| Syndrome | 6 | 2021 | 34 | 0.130 |
Why?
|
| Appetite | 1 | 2016 | 2 | 0.130 |
Why?
|
| Biological Transport | 4 | 2001 | 19 | 0.130 |
Why?
|
| Hyperuricemia | 1 | 2015 | 1 | 0.130 |
Why?
|
| Lisinopril | 1 | 2015 | 1 | 0.130 |
Why?
|
| Body Composition | 3 | 2016 | 27 | 0.130 |
Why?
|
| Diuresis | 1 | 2015 | 1 | 0.130 |
Why?
|
| Oliguria | 1 | 2015 | 1 | 0.130 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 3 | 0.130 |
Why?
|
| Naphthalenes | 2 | 2012 | 6 | 0.130 |
Why?
|
| Chromosome Disorders | 1 | 2015 | 7 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2016 | 64 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 33 | 0.130 |
Why?
|
| Alleles | 1 | 2016 | 214 | 0.130 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 151 | 0.130 |
Why?
|
| Gene Dosage | 1 | 2015 | 13 | 0.130 |
Why?
|
| Mycoplasma | 1 | 2015 | 2 | 0.120 |
Why?
|
| Mycoplasma Infections | 1 | 2015 | 2 | 0.120 |
Why?
|
| Body Size | 2 | 2011 | 7 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 28 | 0.120 |
Why?
|
| Depression | 1 | 2015 | 69 | 0.120 |
Why?
|
| Acute Disease | 5 | 2012 | 79 | 0.120 |
Why?
|
| Hepcidins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2008 | 3 | 0.120 |
Why?
|
| Leptin | 1 | 2014 | 4 | 0.120 |
Why?
|
| Blindness | 1 | 1994 | 1 | 0.120 |
Why?
|
| Genomics | 3 | 2022 | 101 | 0.120 |
Why?
|
| Nutrition Therapy | 1 | 2014 | 2 | 0.120 |
Why?
|
| Reproductive History | 1 | 2014 | 1 | 0.120 |
Why?
|
| Emotions | 3 | 2023 | 22 | 0.120 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 18 | 0.120 |
Why?
|
| Ceramides | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hemoperitoneum | 1 | 1994 | 2 | 0.120 |
Why?
|
| Peritoneal Diseases | 1 | 1994 | 2 | 0.120 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 7 | 0.120 |
Why?
|
| Nutrition Surveys | 3 | 2018 | 7 | 0.120 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2014 | 46 | 0.120 |
Why?
|
| Turkey | 2 | 2018 | 2 | 0.120 |
Why?
|
| Autoanalysis | 1 | 1993 | 1 | 0.110 |
Why?
|
| Phenotype | 4 | 2019 | 257 | 0.110 |
Why?
|
| Income | 1 | 2013 | 17 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 1993 | 14 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2010 | 30 | 0.110 |
Why?
|
| Memory | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 1993 | 1 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2013 | 5 | 0.110 |
Why?
|
| Ownership | 2 | 2023 | 2 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2014 | 24 | 0.110 |
Why?
|
| Adrenal Cortex Diseases | 1 | 1993 | 1 | 0.110 |
Why?
|
| Pyelonephritis | 1 | 1993 | 5 | 0.110 |
Why?
|
| Congenital Hypothyroidism | 1 | 1993 | 4 | 0.110 |
Why?
|
| Adrenal Insufficiency | 1 | 1993 | 4 | 0.110 |
Why?
|
| Minerals | 2 | 2023 | 2 | 0.110 |
Why?
|
| Judgment | 1 | 2012 | 1 | 0.110 |
Why?
|
| Moral Obligations | 1 | 2012 | 1 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 6 | 0.110 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 5 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 45 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 10 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 6 | 1997 | 117 | 0.100 |
Why?
|
| Cytokines | 2 | 2014 | 48 | 0.100 |
Why?
|
| Sclerosis | 2 | 2023 | 2 | 0.100 |
Why?
|
| Steroids | 1 | 2012 | 16 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 231 | 0.100 |
Why?
|
| Resistin | 1 | 2012 | 1 | 0.100 |
Why?
|
| Citrates | 2 | 2021 | 2 | 0.100 |
Why?
|
| Child Behavior Disorders | 2 | 2009 | 6 | 0.100 |
Why?
|
| Aluminum | 3 | 1986 | 3 | 0.100 |
Why?
|
| Urinalysis | 1 | 1992 | 4 | 0.100 |
Why?
|
| Missouri | 1 | 2012 | 81 | 0.100 |
Why?
|
| Oscillometry | 1 | 2011 | 2 | 0.100 |
Why?
|
| Statistics, Nonparametric | 4 | 2018 | 17 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 1992 | 21 | 0.100 |
Why?
|
| Biological Transport, Active | 2 | 2007 | 4 | 0.100 |
Why?
|
| Adiponectin | 1 | 2011 | 3 | 0.100 |
Why?
|
| Enuresis | 1 | 1991 | 1 | 0.100 |
Why?
|
| Acetazolamide | 1 | 1991 | 2 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 81 | 0.100 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 7 | 0.100 |
Why?
|
| Oxidants | 2 | 2022 | 2 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2011 | 5 | 0.100 |
Why?
|
| PAX2 Transcription Factor | 1 | 2011 | 2 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2011 | 5 | 0.100 |
Why?
|
| Renal Artery Obstruction | 1 | 1991 | 2 | 0.100 |
Why?
|
| Hypertension, Renovascular | 1 | 1991 | 4 | 0.100 |
Why?
|
| Age Distribution | 3 | 2008 | 31 | 0.100 |
Why?
|
| Osteolysis | 1 | 1991 | 1 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 84 | 0.090 |
Why?
|
| Self Report | 2 | 2021 | 42 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2021 | 120 | 0.090 |
Why?
|
| F2-Isoprostanes | 2 | 2020 | 3 | 0.090 |
Why?
|
| Liver | 2 | 2006 | 126 | 0.090 |
Why?
|
| Face | 1 | 1990 | 3 | 0.090 |
Why?
|
| Kinetics | 2 | 2001 | 31 | 0.090 |
Why?
|
| Enterococcus | 1 | 2010 | 3 | 0.090 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 1990 | 1 | 0.090 |
Why?
|
| Arthritis, Juvenile | 1 | 1991 | 31 | 0.090 |
Why?
|
| Cytoplasm | 1 | 1990 | 7 | 0.090 |
Why?
|
| Neutrophils | 1 | 1990 | 11 | 0.090 |
Why?
|
| Feeding and Eating Disorders | 1 | 1990 | 8 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2015 | 17 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2010 | 1 | 0.090 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1990 | 2 | 0.090 |
Why?
|
| Japan | 1 | 2010 | 2 | 0.090 |
Why?
|
| Genotype | 3 | 2017 | 410 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1990 | 7 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 3 | 0.090 |
Why?
|
| Hepatoblastoma | 1 | 2010 | 7 | 0.090 |
Why?
|
| Cisplatin | 1 | 2010 | 10 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2009 | 1 | 0.090 |
Why?
|
| Sample Size | 1 | 2009 | 3 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 15 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2009 | 6 | 0.090 |
Why?
|
| Fluorides | 1 | 1989 | 1 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 2 | 2021 | 13 | 0.090 |
Why?
|
| Professional Role | 1 | 2009 | 2 | 0.090 |
Why?
|
| Urinary Incontinence | 1 | 2009 | 3 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2009 | 17 | 0.090 |
Why?
|
| Mycophenolic Acid | 2 | 2007 | 6 | 0.090 |
Why?
|
| Cyclosporine | 2 | 2007 | 6 | 0.090 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 48 | 0.090 |
Why?
|
| Serum Albumin | 6 | 2007 | 9 | 0.090 |
Why?
|
| Patient Participation | 1 | 2009 | 15 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 55 | 0.080 |
Why?
|
| Transplantation Immunology | 2 | 2001 | 2 | 0.080 |
Why?
|
| Niacin | 1 | 1989 | 1 | 0.080 |
Why?
|
| Injections, Intravenous | 4 | 2003 | 15 | 0.080 |
Why?
|
| Flushing | 1 | 1989 | 4 | 0.080 |
Why?
|
| Intellectual Disability | 2 | 2006 | 35 | 0.080 |
Why?
|
| Transplantation | 1 | 2008 | 2 | 0.080 |
Why?
|
| Chemistry, Clinical | 1 | 2008 | 2 | 0.080 |
Why?
|
| Insulin Resistance | 3 | 2014 | 11 | 0.080 |
Why?
|
| Protein C Deficiency | 1 | 1988 | 1 | 0.080 |
Why?
|
| Organ Size | 2 | 2020 | 14 | 0.080 |
Why?
|
| Staphylococcal Infections | 3 | 1997 | 21 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2008 | 12 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 2008 | 5 | 0.080 |
Why?
|
| Equipment Failure | 3 | 2016 | 10 | 0.080 |
Why?
|
| Ultrafiltration | 2 | 2000 | 2 | 0.080 |
Why?
|
| Argentina | 1 | 2007 | 1 | 0.080 |
Why?
|
| Triglycerides | 3 | 2014 | 22 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 1 | 1988 | 22 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2018 | 108 | 0.070 |
Why?
|
| Interleukin-6 | 2 | 2021 | 12 | 0.070 |
Why?
|
| Night Care | 1 | 2007 | 2 | 0.070 |
Why?
|
| Ultrasonography | 6 | 2011 | 46 | 0.070 |
Why?
|
| Antibodies, Bacterial | 3 | 1997 | 8 | 0.070 |
Why?
|
| Congenital Abnormalities | 1 | 2007 | 17 | 0.070 |
Why?
|
| Drainage | 1 | 2007 | 36 | 0.070 |
Why?
|
| Diet Surveys | 2 | 2017 | 3 | 0.070 |
Why?
|
| Internet | 2 | 2023 | 17 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 24 | 0.070 |
Why?
|
| Deferoxamine | 1 | 1986 | 3 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2018 | 19 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2016 | 11 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 8 | 0.070 |
Why?
|
| Milk | 2 | 2017 | 6 | 0.070 |
Why?
|
| Uremia | 2 | 2017 | 2 | 0.070 |
Why?
|
| Capillary Permeability | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cystinosis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 8 | 0.070 |
Why?
|
| Hypertension, Portal | 1 | 2006 | 7 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 23 | 0.070 |
Why?
|
| Propensity Score | 2 | 2017 | 8 | 0.070 |
Why?
|
| Cholesterol | 2 | 2019 | 9 | 0.070 |
Why?
|
| Plasmapheresis | 2 | 2023 | 3 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2017 | 25 | 0.070 |
Why?
|
| Drug Combinations | 3 | 1998 | 19 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2006 | 34 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2006 | 54 | 0.070 |
Why?
|
| Immunoglobulin M | 3 | 2001 | 5 | 0.070 |
Why?
|
| Minority Groups | 1 | 2005 | 17 | 0.060 |
Why?
|
| Haemophilus influenzae | 2 | 1996 | 4 | 0.060 |
Why?
|
| Ureteral Obstruction | 2 | 2011 | 4 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1999 | 3 | 0.060 |
Why?
|
| Exercise | 2 | 2020 | 140 | 0.060 |
Why?
|
| Area Under Curve | 3 | 2012 | 35 | 0.060 |
Why?
|
| Lidocaine | 2 | 1994 | 6 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 35 | 0.060 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 7 | 0.060 |
Why?
|
| Religion and Psychology | 1 | 2004 | 1 | 0.060 |
Why?
|
| Trypanosoma cruzi | 1 | 2004 | 2 | 0.060 |
Why?
|
| Chagas Disease | 1 | 2004 | 2 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2004 | 3 | 0.060 |
Why?
|
| Interpersonal Relations | 1 | 2004 | 11 | 0.060 |
Why?
|
| Luteinizing Hormone | 1 | 2023 | 5 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 40 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2023 | 3 | 0.060 |
Why?
|
| Health Facilities, Proprietary | 1 | 2023 | 1 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 2 | 2001 | 22 | 0.060 |
Why?
|
| Collagen | 1 | 2023 | 3 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2023 | 12 | 0.060 |
Why?
|
| Vasculitis | 2 | 1993 | 2 | 0.060 |
Why?
|
| Immunization | 2 | 2009 | 25 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 4 | 0.050 |
Why?
|
| Forecasting | 2 | 2019 | 22 | 0.050 |
Why?
|
| Hemofiltration | 1 | 2002 | 1 | 0.050 |
Why?
|
| Histoplasma | 1 | 2022 | 3 | 0.050 |
Why?
|
| Health Facility Administration | 1 | 2022 | 1 | 0.050 |
Why?
|
| Organizations, Nonprofit | 1 | 2022 | 3 | 0.050 |
Why?
|
| Escherichia coli O157 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2002 | 5 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2002 | 20 | 0.050 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 1994 | 7 | 0.050 |
Why?
|
| Escherichia coli Infections | 1 | 2002 | 19 | 0.050 |
Why?
|
| Glucocorticoids | 2 | 2017 | 32 | 0.050 |
Why?
|
| Alkalies | 1 | 2022 | 1 | 0.050 |
Why?
|
| Methods | 2 | 2010 | 4 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Gastroenteritis | 1 | 2002 | 28 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 10 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 32 | 0.050 |
Why?
|
| Water-Electrolyte Balance | 1 | 2021 | 1 | 0.050 |
Why?
|
| Nephritis | 1 | 2021 | 1 | 0.050 |
Why?
|
| Brain Death | 1 | 2001 | 3 | 0.050 |
Why?
|
| Birth Weight | 1 | 2021 | 28 | 0.050 |
Why?
|
| Sugar Acids | 1 | 2021 | 1 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sulfides | 1 | 2021 | 6 | 0.050 |
Why?
|
| Diffusion | 2 | 2002 | 4 | 0.050 |
Why?
|
| Tryptophan | 1 | 2021 | 4 | 0.050 |
Why?
|
| Lamins | 1 | 2021 | 1 | 0.050 |
Why?
|
| Smad Proteins | 1 | 2021 | 1 | 0.050 |
Why?
|
| South America | 2 | 2011 | 2 | 0.050 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2001 | 1 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2021 | 4 | 0.050 |
Why?
|
| Fever | 1 | 2021 | 26 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2021 | 6 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 7 | 0.050 |
Why?
|
| Puberty | 1 | 2021 | 7 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 77 | 0.050 |
Why?
|
| Organophosphates | 1 | 2021 | 1 | 0.050 |
Why?
|
| Liver Circulation | 1 | 2001 | 2 | 0.050 |
Why?
|
| Ischemia | 1 | 2001 | 7 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2001 | 5 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2021 | 25 | 0.050 |
Why?
|
| Apoptosis | 1 | 2021 | 52 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2000 | 8 | 0.050 |
Why?
|
| China | 1 | 2020 | 9 | 0.050 |
Why?
|
| Prescriptions | 1 | 2020 | 9 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2000 | 14 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2020 | 14 | 0.050 |
Why?
|
| Buffers | 1 | 2020 | 2 | 0.050 |
Why?
|
| Thyrotropin | 1 | 2020 | 3 | 0.050 |
Why?
|
| Curriculum | 1 | 2000 | 22 | 0.050 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2020 | 20 | 0.050 |
Why?
|
| Epidemics | 1 | 2020 | 1 | 0.050 |
Why?
|
| Behavior Rating Scale | 1 | 2020 | 1 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 17 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 25 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 6 | 0.040 |
Why?
|
| Thorax | 1 | 2000 | 4 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 9 | 0.040 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2019 | 2 | 0.040 |
Why?
|
| Ganciclovir | 1 | 1999 | 3 | 0.040 |
Why?
|
| Cats | 1 | 1999 | 4 | 0.040 |
Why?
|
| Cholangitis | 1 | 1999 | 3 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 7 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 10 | 0.040 |
Why?
|
| Membranes | 1 | 1999 | 2 | 0.040 |
Why?
|
| Administration, Intranasal | 2 | 1997 | 8 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 1 | 0.040 |
Why?
|
| Carrier State | 2 | 1997 | 5 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2019 | 26 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2012 | 12 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 45 | 0.040 |
Why?
|
| Abnormalities, Multiple | 1 | 2000 | 36 | 0.040 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1999 | 1 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 1999 | 30 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2019 | 11 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 6 | 0.040 |
Why?
|
| Americas | 1 | 2019 | 1 | 0.040 |
Why?
|
| Truth Disclosure | 1 | 2019 | 3 | 0.040 |
Why?
|
| Policy Making | 1 | 2019 | 3 | 0.040 |
Why?
|
| Informed Consent | 1 | 2019 | 4 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 17 | 0.040 |
Why?
|
| Health Policy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Thrombosis | 1 | 1999 | 15 | 0.040 |
Why?
|
| Blood Glucose | 1 | 1999 | 61 | 0.040 |
Why?
|
| Reference Standards | 2 | 2009 | 15 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 150 | 0.040 |
Why?
|
| Absenteeism | 1 | 2018 | 2 | 0.040 |
Why?
|
| Bronchopulmonary Dysplasia | 2 | 1993 | 40 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 19 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 8 | 0.040 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1998 | 2 | 0.040 |
Why?
|
| Systole | 1 | 2018 | 10 | 0.040 |
Why?
|
| Mice | 2 | 2017 | 348 | 0.040 |
Why?
|
| Splenectomy | 1 | 1998 | 8 | 0.040 |
Why?
|
| Chromium | 1 | 1998 | 1 | 0.040 |
Why?
|
| Haplotypes | 1 | 2018 | 91 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 18 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 23 | 0.040 |
Why?
|
| Complement C3d | 1 | 2017 | 1 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2017 | 1 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Omentum | 1 | 2017 | 3 | 0.040 |
Why?
|
| Smad2 Protein | 1 | 2017 | 3 | 0.040 |
Why?
|
| Complement C1q | 1 | 2017 | 3 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2017 | 6 | 0.040 |
Why?
|
| Proteome | 1 | 2017 | 3 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2017 | 22 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 8 | 0.040 |
Why?
|
| Bioethical Issues | 1 | 2017 | 3 | 0.040 |
Why?
|
| Urinary Calculi | 1 | 1997 | 3 | 0.040 |
Why?
|
| Age of Onset | 1 | 2017 | 28 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 2017 | 1 | 0.040 |
Why?
|
| Manometry | 1 | 2017 | 3 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 4 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 2017 | 1 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2017 | 1 | 0.040 |
Why?
|
| Fast Foods | 1 | 2017 | 3 | 0.040 |
Why?
|
| Zebrafish | 1 | 2017 | 10 | 0.040 |
Why?
|
| Fruit | 1 | 2017 | 10 | 0.040 |
Why?
|
| Models, Animal | 1 | 2017 | 10 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 1997 | 22 | 0.040 |
Why?
|
| Diphtheria Toxoid | 1 | 1997 | 1 | 0.040 |
Why?
|
| Measles Vaccine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Mumps Vaccine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Rubella Vaccine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1997 | 2 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 5 | 0.040 |
Why?
|
| Transcriptome | 1 | 2017 | 59 | 0.040 |
Why?
|
| Mupirocin | 1 | 1997 | 3 | 0.040 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1997 | 3 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 53 | 0.040 |
Why?
|
| Heterozygote | 1 | 2017 | 26 | 0.040 |
Why?
|
| Exome | 1 | 2017 | 36 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 2 | 0.040 |
Why?
|
| Ion Transport | 1 | 1996 | 1 | 0.040 |
Why?
|
| Ostomy | 1 | 2016 | 5 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1997 | 15 | 0.040 |
Why?
|
| Injections, Subcutaneous | 3 | 2003 | 8 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2017 | 132 | 0.040 |
Why?
|
| Device Removal | 1 | 2016 | 14 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 115 | 0.030 |
Why?
|
| Self Concept | 1 | 1996 | 8 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 21 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 1 | 1996 | 1 | 0.030 |
Why?
|
| HLA-A Antigens | 1 | 1996 | 2 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1996 | 4 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 1996 | 7 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 1996 | 5 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1996 | 46 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 20 | 0.030 |
Why?
|
| Activity Cycles | 1 | 2015 | 1 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 115 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 40 | 0.030 |
Why?
|
| Seasons | 1 | 2015 | 35 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 4 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 10 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 12 | 0.030 |
Why?
|
| Pancreas | 1 | 1995 | 8 | 0.030 |
Why?
|
| Dogs | 1 | 2015 | 17 | 0.030 |
Why?
|
| Peritoneal Cavity | 2 | 1997 | 3 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 4 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 1994 | 3 | 0.030 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1994 | 1 | 0.030 |
Why?
|
| Health Facilities | 1 | 1994 | 1 | 0.030 |
Why?
|
| Medical Staff | 1 | 1994 | 1 | 0.030 |
Why?
|
| Clotrimazole | 1 | 2014 | 3 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 24 | 0.030 |
Why?
|
| Fetal Development | 1 | 2014 | 4 | 0.030 |
Why?
|
| Environment | 1 | 2014 | 8 | 0.030 |
Why?
|
| Insulin | 1 | 2014 | 50 | 0.030 |
Why?
|
| Pain | 1 | 1994 | 57 | 0.030 |
Why?
|
| Lactosylceramides | 1 | 2014 | 1 | 0.030 |
Why?
|
| Bacitracin | 1 | 1994 | 1 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 1994 | 1 | 0.030 |
Why?
|
| Rifampin | 1 | 1994 | 7 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2009 | 12 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 1 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 1993 | 5 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 17 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 37 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 1993 | 5 | 0.030 |
Why?
|
| DNA Primers | 1 | 1993 | 30 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 6 | 0.030 |
Why?
|
| Fructose | 1 | 1993 | 1 | 0.030 |
Why?
|
| Glycoside Hydrolases | 1 | 1993 | 2 | 0.030 |
Why?
|
| Radiography | 2 | 1991 | 37 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1993 | 71 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 5 | 0.030 |
Why?
|
| Base Sequence | 1 | 1993 | 81 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 43 | 0.030 |
Why?
|
| Nephrosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 1993 | 1 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 1993 | 1 | 0.030 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 1993 | 1 | 0.030 |
Why?
|
| Cotinine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Brain Diseases | 1 | 1993 | 6 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 1993 | 16 | 0.030 |
Why?
|
| Nitrites | 1 | 1993 | 1 | 0.030 |
Why?
|
| Urine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Bacteroides Infections | 1 | 1993 | 1 | 0.030 |
Why?
|
| Lymphatic System | 1 | 1993 | 1 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1993 | 13 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1993 | 5 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 19 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 2 | 0.030 |
Why?
|
| Meningitis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Aldosterone | 1 | 1992 | 1 | 0.030 |
Why?
|
| Hypophosphatemia, Familial | 1 | 1992 | 1 | 0.030 |
Why?
|
| Nephrocalcinosis | 1 | 1992 | 1 | 0.030 |
Why?
|
| Calcitriol | 1 | 1992 | 6 | 0.030 |
Why?
|
| White Coat Hypertension | 1 | 2012 | 1 | 0.030 |
Why?
|
| Algorithms | 2 | 2004 | 105 | 0.030 |
Why?
|
| Lipids | 1 | 2012 | 8 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 16 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2012 | 5 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 15 | 0.030 |
Why?
|
| Reagent Strips | 1 | 1992 | 1 | 0.030 |
Why?
|
| Residential Facilities | 1 | 1992 | 1 | 0.030 |
Why?
|
| Bacteriuria | 1 | 1992 | 2 | 0.030 |
Why?
|
| Auscultation | 1 | 2011 | 1 | 0.030 |
Why?
|
| Plagiarism | 1 | 1991 | 1 | 0.030 |
Why?
|
| Sphygmomanometers | 1 | 2011 | 1 | 0.030 |
Why?
|
| Rest | 1 | 2011 | 4 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 1991 | 18 | 0.020 |
Why?
|
| Pyridoxal Phosphate | 1 | 1991 | 1 | 0.020 |
Why?
|
| Riboflavin | 1 | 1991 | 1 | 0.020 |
Why?
|
| Thiamine | 1 | 1991 | 2 | 0.020 |
Why?
|
| Vitamin A | 1 | 1991 | 3 | 0.020 |
Why?
|
| Diet Records | 1 | 1991 | 5 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 1991 | 9 | 0.020 |
Why?
|
| Acidosis, Renal Tubular | 1 | 1991 | 1 | 0.020 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 1991 | 1 | 0.020 |
Why?
|
| Imipramine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Sodium Bicarbonate | 1 | 1991 | 1 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 1991 | 6 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 1991 | 3 | 0.020 |
Why?
|
| Folic Acid | 1 | 1991 | 17 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 1991 | 7 | 0.020 |
Why?
|
| Counseling | 1 | 1991 | 28 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 1991 | 35 | 0.020 |
Why?
|
| Latin America | 1 | 2010 | 1 | 0.020 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2010 | 1 | 0.020 |
Why?
|
| Risk | 2 | 2008 | 41 | 0.020 |
Why?
|
| Republic of Korea | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2010 | 15 | 0.020 |
Why?
|
| Infant Care | 1 | 1990 | 3 | 0.020 |
Why?
|
| Cold Ischemia | 1 | 2009 | 1 | 0.020 |
Why?
|
| Urination Disorders | 1 | 1990 | 4 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 9 | 0.020 |
Why?
|
| Psychology, Child | 1 | 1990 | 12 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 5 | 0.020 |
Why?
|
| Seizures | 2 | 1993 | 25 | 0.020 |
Why?
|
| Fluoridation | 1 | 1989 | 1 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 1990 | 37 | 0.020 |
Why?
|
| Hyperostosis, Cortical, Congenital | 1 | 1989 | 2 | 0.020 |
Why?
|
| Joint Diseases | 1 | 1989 | 4 | 0.020 |
Why?
|
| Cross-Over Studies | 2 | 2002 | 35 | 0.020 |
Why?
|
| Biometry | 1 | 2009 | 1 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 9 | 0.020 |
Why?
|
| Protein C | 1 | 1988 | 1 | 0.020 |
Why?
|
| Prothrombin | 1 | 1988 | 1 | 0.020 |
Why?
|
| Twins | 1 | 1988 | 3 | 0.020 |
Why?
|
| Heparin | 1 | 1988 | 6 | 0.020 |
Why?
|
| Motor Skills | 1 | 1988 | 3 | 0.020 |
Why?
|
| Ceftazidime | 1 | 2008 | 4 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 1 | 0.020 |
Why?
|
| Family Relations | 1 | 2008 | 2 | 0.020 |
Why?
|
| Learning | 1 | 2008 | 5 | 0.020 |
Why?
|
| Comprehension | 1 | 2008 | 3 | 0.020 |
Why?
|
| Esthetics | 1 | 2008 | 7 | 0.020 |
Why?
|
| Peer Group | 1 | 2008 | 7 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 11 | 0.020 |
Why?
|
| Azathioprine | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2007 | 2 | 0.020 |
Why?
|
| Absorption | 1 | 2007 | 7 | 0.020 |
Why?
|
| Anemia, Hypochromic | 1 | 1986 | 1 | 0.020 |
Why?
|
| Osteomalacia | 1 | 1986 | 2 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 8 | 0.020 |
Why?
|
| Solutions | 1 | 1986 | 3 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2006 | 5 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1986 | 5 | 0.020 |
Why?
|
| Food, Formulated | 1 | 1986 | 4 | 0.020 |
Why?
|
| Urethra | 1 | 1986 | 5 | 0.020 |
Why?
|
| Proteins | 1 | 1986 | 27 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 18 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 5 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1985 | 8 | 0.020 |
Why?
|
| Malnutrition | 1 | 2005 | 8 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 50 | 0.020 |
Why?
|
| Rats | 2 | 1996 | 106 | 0.020 |
Why?
|
| Acinetobacter Infections | 1 | 1984 | 1 | 0.020 |
Why?
|
| Dysarthria | 1 | 1984 | 1 | 0.020 |
Why?
|
| Personality Disorders | 1 | 1984 | 1 | 0.020 |
Why?
|
| Serratia | 1 | 1984 | 1 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 1984 | 2 | 0.020 |
Why?
|
| Speech Disorders | 1 | 1984 | 3 | 0.020 |
Why?
|
| Equipment Contamination | 1 | 1984 | 6 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 1984 | 7 | 0.020 |
Why?
|
| Anaerobic Threshold | 1 | 2004 | 1 | 0.010 |
Why?
|
| Exercise Test | 1 | 2004 | 17 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 2004 | 1 | 0.010 |
Why?
|
| Radioimmunoprecipitation Assay | 1 | 2004 | 1 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 2002 | 1 | 0.010 |
Why?
|
| Convection | 1 | 2002 | 1 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 8 | 0.010 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 1982 | 2 | 0.010 |
Why?
|
| Critical Illness | 1 | 2002 | 22 | 0.010 |
Why?
|
| Craniocerebral Trauma | 1 | 2001 | 18 | 0.010 |
Why?
|
| Antibody Formation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2001 | 1 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2001 | 13 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2000 | 4 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2001 | 19 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2001 | 23 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2000 | 17 | 0.010 |
Why?
|
| Bilirubin | 1 | 2000 | 26 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2000 | 16 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 12 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2000 | 17 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2000 | 39 | 0.010 |
Why?
|
| Education | 1 | 1999 | 3 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2000 | 115 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1998 | 1 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1998 | 2 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1998 | 2 | 0.010 |
Why?
|
| Organ Preservation | 1 | 1998 | 6 | 0.010 |
Why?
|
| Rubella virus | 1 | 1997 | 1 | 0.010 |
Why?
|
| Vaccines, Combined | 1 | 1997 | 1 | 0.010 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 1997 | 2 | 0.010 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 1997 | 2 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 20 | 0.010 |
Why?
|
| Permeability | 1 | 1996 | 7 | 0.010 |
Why?
|
| Kidney Medulla | 1 | 1996 | 3 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1996 | 8 | 0.010 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1996 | 13 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1996 | 10 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 1997 | 187 | 0.010 |
Why?
|
| Random Allocation | 1 | 1994 | 7 | 0.010 |
Why?
|
| Haemophilus Vaccines | 1 | 1993 | 2 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1993 | 3 | 0.010 |
Why?
|
| Home Care Services | 1 | 1993 | 6 | 0.010 |
Why?
|
| Electroencephalography | 1 | 1993 | 7 | 0.010 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1993 | 1 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1993 | 30 | 0.010 |
Why?
|
| Calcium Phosphates | 1 | 1992 | 1 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 5 | 0.010 |
Why?
|
| Captopril | 1 | 1992 | 1 | 0.010 |
Why?
|
| Age Determination by Skeleton | 1 | 1990 | 1 | 0.010 |
Why?
|
| Anthropometry | 1 | 1990 | 15 | 0.010 |
Why?
|
| Elbow Joint | 1 | 1989 | 2 | 0.010 |
Why?
|
| Urography | 1 | 1987 | 2 | 0.000 |
Why?
|
| Genes, Dominant | 1 | 1987 | 5 | 0.000 |
Why?
|
| Tremor | 1 | 1984 | 1 | 0.000 |
Why?
|
| Bone and Bones | 1 | 1984 | 17 | 0.000 |
Why?
|
| Propranolol | 1 | 1984 | 1 | 0.000 |
Why?
|
| Hydrochlorothiazide | 1 | 1984 | 2 | 0.000 |
Why?
|
| Renin | 1 | 1982 | 1 | 0.000 |
Why?
|
| Renal Veins | 1 | 1982 | 3 | 0.000 |
Why?
|
| Renal Artery | 1 | 1982 | 5 | 0.000 |
Why?
|